Erratum: Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB

Vasilisa Aksenova; Lidia Turoverova; Mikhail Khotin; Karl-Eric Magnusson; Eugene Tulchinsky; Gerry Melino; George P. Pinaev; Nickolai Barlev; Dmitri Tentler

doi:10.18632/oncotarget.26206

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Errata:

Erratum: Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB

PDF | How to cite

Oncotarget. 2018; 9:34450-34450. https://doi.org/10.18632/oncotarget.26206

Metrics: PDF 2686 views | ?

Vasilisa Aksenova^1,2, Lidia Turoverova¹, Mikhail Khotin¹, Karl-Eric Magnusson³, Eugene Tulchinsky⁴, Gerry Melino^2,5, George P. Pinaev¹, Nickolai Barlev^1,2,6, and Dmitri Tentler^1,2

¹ Institute of Cytology, Russian Academy of Sciences, Tikhoretsky av., 4, St. Petersburg, Russia
² Laboratory of Molecular Pharmacology, Saint-Petersburg Technological Institute, 26 Moskovsky Prospect, St. Petersburg, Russia
³ Division of Medical Microbiology, Department of Clinical and Experimental Medicine, Linköping University, SE-581 85 Linköping, Sweden
⁴ Department of Cancer Studies and Molecular Medicine, University of Leicester, RKCSB, LRI, Leicester, UK
⁵ MRC Toxicology Unit, Leicester, UK
⁶ Department of Biochemistry, University of Leicester, Lancaster Road, Leicester, UK

Published: September 28, 2018

This article has been corrected: During production, the ending page number for this article was listed incorrectly. The page count has now been adjusted to show the proper pagination.

Original article: Oncotarget. 2012; 4:362-372. DOI: https://doi.org/10.18632/oncotarget.901.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26206

Publication Alerts

Post-Publication Promotion

Publication Discount

Errata:

Erratum: Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB